Cellectar Biosciences, Inc. — Director's Dealing 2023

Jan 19, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2023-01-17

Reporting Person: Kolean Chad J (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-17	Stock option (right to buy)	$1.68	A	104000	Acquired	2033-01-17	Common Stock (104000)	Direct

Footnotes

F1: This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.